BMA
MRK icon

Brooks Moore & Associates’s Merck MRK Stock Holding History

Brooks Moore & Associates’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.7M Sell
30,769
-1,415
-4% -$163K 1.86% 18
2025
Q4 		$3.39M Sell
32,184
-15
-0% -$1.41K 1.67% 20
2025
Q3 		$2.7M Sell
32,199
-14,957
-32% -$1.23M 1.37% 24
2025
Q2 		$3.68M Sell
47,156
-425
-0.9% -$33.8K 1.99% 18
2025
Q1 		$4.27M Sell
47,581
-175
-0.4% -$16.3K 2.41% 12
2024
Q4 		$4.75M Buy
47,756
+220
+0.5% +$22.7K 2.81% 10
2024
Q3 		$5.4M Buy
47,536
+406
+0.9% +$48.2K 3.19% 7
2024
Q2 		$5.83M Sell
47,130
-395
-0.8% -$50.9K 3.75% 4
2024
Q1 		$6.27M Sell
47,525
-49
-0.1% -$6.04K 4.02% 3
2023
Q4 		$5.19M Sell
47,574
-168
-0.4% -$17.4K 3.56% 6
2023
Q3 		$4.92M Buy
47,742
+1,312
+3% +$141K 3.71% 5
2023
Q2 		$5.36M Sell
46,430
-225
-0.5% -$25.5K 3.77% 4
2023
Q1 		$4.96M Buy
46,655
+1,856
+4% +$200K 3.57% 4
2022
Q4 		$4.97M Sell
44,799
-761
-2% -$77.8K 3.63% 6
2022
Q3 		$3.92M Sell
45,560
-577
-1% -$51.5K 3.17% 7
2022
Q2 		$4.21M Sell
46,137
-975
-2% -$86.4K 3.03% 8
2022
Q1 		$3.87M Sell
47,112
-725
-2% -$57.2K 2.37% 11
2021
Q4 		$3.67M Sell
47,837
-250
-0.5% -$19.9K 2.15% 16
2021
Q3 		$3.61M Buy
48,087
+75
+0.2% +$5.7K 2.36% 10
2021
Q2 		$3.73M Buy
48,012
+4,268
+10% +$317K 2.38% 8
2021
Q1 		$3.22M Buy
43,744
+5,324
+14% +$393K 2.18% 14
2020
Q4 		$3M Buy
38,420
+655
+2% +$50.1K 2.32% 12
2020
Q3 		$2.99M Sell
37,765
-652
-2% -$51.1K 2.58% 9
2020
Q2 		$2.83M Buy
38,417
+1,727
+5% +$130K 2.65% 8
2020
Q1 		$2.69M Sell
36,690
-524
-1% -$41.2K 2.86% 5
2019
Q4 		$3.23M Buy
37,214
+1,208
+3% +$99.2K 2.56% 6
2019
Q3 		$2.89M Buy
36,006
+592
+2% +$47.4K 2.44% 6
2019
Q2 		$2.83M Buy
35,414
+941
+3% +$72.1K 2.43% 8
2019
Q1 		$2.74M Sell
34,473
-592
-2% -$44.3K 2.5% 9
2018
Q4 		$2.56M Buy
+35,065
New +$2.48M 2.57% 7

Other funds holding MRK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brooks Moore & Associates's MRK Position: Q1 2026 in Review

Brooks Moore & Associates reduced its Merck (MRK) stake by 4.4% in Q1 2026, selling an estimated $163K and leaving 30,769 shares worth $3.7M. The position accounts for 1.86% of the portfolio, ranked #18.

Brooks Moore & Associates first reported a position in MRK in Q4 2018 and has held it in 30 quarters since. The position peaked at $6.27M in Q1 2024. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Brooks Moore & Associates held 30,769 shares of Merck worth $3.7M as of Q1 2026.
  • Brooks Moore & Associates sold 1,415 Merck shares in Q1 2026, an estimated $163K.
  • Merck made up 1.86% of Brooks Moore & Associates's portfolio in Q1 2026, its #18 holding.
  • Brooks Moore & Associates first reported a position in Merck in Q4 2018 and has held it in 30 quarters since.
  • Brooks Moore & Associates's Merck position peaked at $6.27M in Q1 2024.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Brooks Moore & Associates's 13F filing for Q1 2026, filed 15 May 2026.